Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Active, not recruiting
Eidos Therapeutics
Phase 3
2019-03-19
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) 800 mg administered orally
twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid
Cardiomyopathy (ATTR-CM).
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Active, not recruiting
Eidos Therapeutics, a BridgeBio company
Phase 3
2019-03-19
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) 800 mg administered orally
twice a day compared to placebo in subjects with symptomatic Transthyretin Amyloid
Cardiomyopathy (ATTR-CM).
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Active, not recruiting
Eidos Therapeutics
Phase 3
2020-11-01
This prospective study is designed to evaluate the efficacy, safety, and tolerability of
ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and
pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a
background of stable heart failure therapy.
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Active, not recruiting
Eidos Therapeutics, a BridgeBio company
Phase 3
2020-11-01
This prospective study is designed to evaluate the efficacy, safety, and tolerability of
ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and
pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a
background of stable heart failure therapy.
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
Active, not recruiting
Alexion Pharmaceuticals
Phase 3
2020-11-01
This prospective study is designed to evaluate the efficacy, safety, and tolerability of
ALXN2060 (also known as AG10), as well as to establish its pharmacokinetic and
pharmacodynamic profile in Japanese participants with symptomatic ATTR-CM administered on a
background of stable heart failure therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
